

# Canada

Population 2015

36 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.11 (0.1–0.11)	0.29 (0.29–0.3)
Mortality (HIV+TB only)	0.019 (<0.01–0.096)	0.05 (0–0.27)
Incidence (includes HIV+TB)	1.8 (1.6–2.1)	5.1 (4.3–5.8)
Incidence (HIV+TB only)	0.15 (0.12–0.17)	0.4 (0.33–0.48)
Incidence (MDR/RR-TB)**	0.031 (0.016–0.045)	0.09 (0.04–0.13)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.058 (0.032–0.084)	0.74 (0.56–0.92)	0.8 (0.59–1)
Males	0.055 (0.036–0.074)	0.97 (0.76–1.2)	1 (0.8–1.3)
Total	0.11 (0.08–0.15)	1.7 (1.6–1.9)	1.8 (1.6–2.1)

## TB case notifications, 2015

Total cases notified	1 640
Total new and relapse	1 640
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	44%
- % pulmonary	70%
- % bacteriologically confirmed among pulmonary	80%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	90% (78–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.07 (0.04–0.1)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	58	8%
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			16 (8–25)
Estimated % of TB cases with MDR/RR-TB	1.4% (0.72–2.4)	1.8% (0.05–9.6)	
% notified tested for rifampicin resistance	76%	78%	1 268
MDR/RR-TB cases tested for resistance to second-line drugs			19
Laboratory-confirmed cases		MDR/RR-TB: 19, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	82%	1 612
Previously treated cases, excluding relapse, registered in 2014		
HIV-positive TB cases, all types, registered in 2014	74%	65
MDR/RR-TB cases started on second-line treatment in 2013	67%	15
XDR-TB cases started on second-line treatment in 2013	100%	1

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2016

National TB budget (US\$ millions)	
------------------------------------	--

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015



## Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB